Napoleon Bonaparte issued a proclamation to the Jews of Palestine promising the “reestablishment of ancient Jerusalem,” coupled with a plea for their support. This was the first promise by a modern ...

One in four patients who present with elevated low-density lipoprotein cholesterol levels have no documented use of statin therapy, according to a study published April 16 in Epic Research.  Here are ...

An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

Nongenetic factors and rare genetic variants were sources of variation that could influence the association between age at menarche and CAD.

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

A large study of 133,764 adults found that a voluntary digital lifestyle program reduced 10-year diabetes risk by 45.6% in prediabetics and doubled remission rates in diabetics, with significant ...

A study published in the British Medical Journal investigated the relationship between baseline low-density lipoprotein cholesterol (LDL-C) levels and the | Immunology ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Verve shares Phase 1b results of VERVE-102, showing dose-dependent LDL-C reductions and strong safety in patients with HeFH ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

The focus is on a drug called Lepodisiran, that could target certain factors that increase risk of heart attacks and strokes.